人胃癌SGC-7901/HCPT裸鼠移植瘤的建立及生物學特性研究_《中國普外基礎與臨床雜志》

作者：

王攀 , 魏壽江 , 何一 , 侯華芳 , 王崇樹

川北醫學院附屬醫院普外科（四川南充 637000）;

關鍵詞：

胃癌羥喜樹堿裸鼠移植瘤耐藥

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的建立人胃癌羥喜樹堿（HCPT）耐藥細胞系SGC-7901/HCPT裸鼠皮下移植瘤模型并研究其生物學特征。方法體外培養人胃癌細胞系SGC-7901和SGC-7901/HCPT，采用皮下注射方式分別接種至裸小鼠，待腫瘤長徑達1.0 cm時，將其切下剪成直徑為0.1～0.2 cm小塊，再接種至第2代裸鼠皮下進行傳代，重復至第4代。對第4代移植瘤光鏡下的組織學形態、電鏡下的超微結構及生長特點進行觀察，四甲基偶氮唑鹽（MTT）法檢測其耐藥性。結果裸鼠皮下移植瘤呈圓形或橢圓形，表面可見豐富的血管網。光鏡下見親代細胞移植瘤的細胞大小基本一致，排列較整齊，細胞核的大小較一致；而耐藥細胞移植瘤的細胞形態較不規則，排列紊亂，細胞核的大小差異較大。電鏡下見親代細胞移植瘤細胞的細胞核無腫脹，線粒體及內質網基本正常；耐藥細胞移植瘤細胞的細胞核略腫脹，核異染色質凝集，線粒體及內質網腫脹較明顯。與親代細胞第4代移植瘤相比較，耐藥細胞第4代移植瘤對HCPT的耐藥指數為9.02±0.78，對阿霉素、絲裂霉素C、5-氟尿嘧啶及依托泊苷的耐藥指數分別為1.24±0.09、1.31±0.17、0.96±0.12和1.07±0.16。結論本實驗建立了穩定的人胃癌HCPT耐藥細胞系SGC-7901/HCPT裸鼠移植瘤模型，耐藥細胞對HCPT的耐藥性保持穩定，且對其他化療藥物無交叉耐藥性，可用于下游實驗研究。

引用本文： 王攀,魏壽江,何一,侯華芳,王崇樹. 人胃癌SGC-7901/HCPT裸鼠移植瘤的建立及生物學特性研究. 中國普外基礎與臨床雜志, 2010, 17(11): 1147-1151. doi: 復制

1.	Meyer HJ. The influence of case load and the extent of resection on the quality of treatment outcome in gastric cancer [J]. Eur J Surg Oncol, 2005; 31(6): 595-604.
2.	Sivins A, Pedrazzani C, Roviello F, et al. Surgical treatment of gastric cancer in Latvia: results of centralized experience [J]. Eur J Surg Oncol, 2009; 35(5): 481-485.
3.	Morabito A, Carillio G, Longo R. Systemic treatment of gastric cancer [J]. Crit Rev Oncol Hematol, 2009; 70(3): 216-234.
4.	Cervenak J, Andrikovics H, Ozvegy-Laczka C, et al. The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology [J]. Cancer Lett, 2006; 234(1): 62-72.
5.	Chun JH, Kim HK, Lee JS, et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy [J]. Jpn J Clin Oncol, 2004; 34(1): 8-13.
6.	林蕓秀, 呂聯煌, 林錦娟, 等. 人小細胞肺癌NCI-H446細胞裸鼠異種移植瘤模型的建立 [J]. 實驗動物科學與管理, 2004; 21(3): 1-3.
7.	何一, 王崇樹, 魏壽江, 等. 人胃癌耐羥基喜樹堿細胞株SGC-7901/HCPT 的建立及其生物學性狀 [J]. 中國現代醫生, 2008; 46(3): 15-17.
8.	Branimir IS. Natural and Acquired Resistance to Cancer Therapies [A]. In: John Mendelsohn MD, Peter M. Howley MD, Mark A. Israel MD, et al. The Molecular Basis of Cancer [M]. Third Ed, 2008: 583-592.
9.	Morgillo F, Bareschino MA, Bianco R, et al. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy [J]. Differentiation, 2007; 75(9): 788-799.
10.	Duesberg P, Li R, Sachs R, et al. Cancer drug resistance: the central role of the karyotype [J]. Drug Resist Updat, 2007; 10(1-2): 51-58.
11.	Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer [J]. FEBS Lett, 2006; 580(12): 2903-2909.
12.	Jabr-Milane LS, van Vlerken LE, Yadav S, et al. Multi-functional nanocarriers to overcome tumor drug resistance [J]. Cancer Treat Rev, 2008; 34(7): 592-602.
13.	McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer [J]. Drug Resist Updat, 2008; 11(4-5): 164-179.
14.	Rygaard J, Povlsen CO. Hetero transplantation of a human malignant tumor to nude mice [J]. Act Path Microbiol Scand, 1969; 77(4): 758-760.
15.	劉孟剛, 楊俊濤, 劉宏鳴, 等. GA反義基因對裸鼠胃癌移植瘤細胞凋亡的影響 [J]. 中國普外基礎與臨床雜志, 2008; 15(1): 4-7.
16.	黃喆, 郭克建, 何三光. 柳氮磺胺吡啶和5-氟尿嘧啶對裸鼠皮下移植瘤胰腺癌細胞BxPC-3凋亡基因的影響 [J]. 中國普外基礎與臨床雜志, 2008; 15(8): 550-555.
17.	Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial [J]. Lancet, 2001; 358(9286): 966-970.
18.	Metzinger DS, Taylor DD, Gercel-Taylor C. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines [J]. Cancer Lett, 2006; 236(2): 302-308.
19.	萬繼英, 韓庶勇. 腫瘤實驗動物模型的建立及應用研究進展 [J]. 醫學綜述， 2009; 15(19): 2959-2961.
20.	Yoshiba S, Ito D, Nagumo T, et al. Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest [J]. Oral Oncol, 2009; 45(2): 109-115.
21.	梁永鉅，符立梧，馮海林, 等. KBv200裸鼠移植瘤模型的建立及其耐藥特性的探討 [J] . 中國藥理學通報, 2000; 16(6)： 705-707.
22.	Henss H, Fiebig HH, Meinhardt K, et al. Clonal growth of human tumor xenografts. First experiences in drug testing [J]. J Cancer Res Clin Oncol, 1984; 108(2): 233-235.
23.	Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development [J]. Eur J Cancer, 2004; 40(6): 827-836.
24.	Prenen H, Deroose C, Vermaelen P, et al. Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography [J]. Anticancer Res, 2006; 26(2A): 1247-1252.
25.	Zhang YH, Wu Q, Xiao XY, et al. Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell [J]. Cancer Lett, 2010; 291(1): 76-82.
26.	Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic plafform [J]. Lancet Oncol, 2002; 3(1): 17-26.

1. Meyer HJ. The influence of case load and the extent of resection on the quality of treatment outcome in gastric cancer [J]. Eur J Surg Oncol, 2005; 31(6): 595-604.
2. Sivins A, Pedrazzani C, Roviello F, et al. Surgical treatment of gastric cancer in Latvia: results of centralized experience [J]. Eur J Surg Oncol, 2009; 35(5): 481-485.
3. Morabito A, Carillio G, Longo R. Systemic treatment of gastric cancer [J]. Crit Rev Oncol Hematol, 2009; 70(3): 216-234.
4. Cervenak J, Andrikovics H, Ozvegy-Laczka C, et al. The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology [J]. Cancer Lett, 2006; 234(1): 62-72.
5. Chun JH, Kim HK, Lee JS, et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy [J]. Jpn J Clin Oncol, 2004; 34(1): 8-13.
6. 林蕓秀, 呂聯煌, 林錦娟, 等. 人小細胞肺癌NCI-H446細胞裸鼠異種移植瘤模型的建立 [J]. 實驗動物科學與管理, 2004; 21(3): 1-3.
7. 何一, 王崇樹, 魏壽江, 等. 人胃癌耐羥基喜樹堿細胞株SGC-7901/HCPT 的建立及其生物學性狀 [J]. 中國現代醫生, 2008; 46(3): 15-17.
8. Branimir IS. Natural and Acquired Resistance to Cancer Therapies [A]. In: John Mendelsohn MD, Peter M. Howley MD, Mark A. Israel MD, et al. The Molecular Basis of Cancer [M]. Third Ed, 2008: 583-592.
9. Morgillo F, Bareschino MA, Bianco R, et al. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy [J]. Differentiation, 2007; 75(9): 788-799.
10. Duesberg P, Li R, Sachs R, et al. Cancer drug resistance: the central role of the karyotype [J]. Drug Resist Updat, 2007; 10(1-2): 51-58.
11. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer [J]. FEBS Lett, 2006; 580(12): 2903-2909.
12. Jabr-Milane LS, van Vlerken LE, Yadav S, et al. Multi-functional nanocarriers to overcome tumor drug resistance [J]. Cancer Treat Rev, 2008; 34(7): 592-602.
13. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer [J]. Drug Resist Updat, 2008; 11(4-5): 164-179.
14. Rygaard J, Povlsen CO. Hetero transplantation of a human malignant tumor to nude mice [J]. Act Path Microbiol Scand, 1969; 77(4): 758-760.
15. 劉孟剛, 楊俊濤, 劉宏鳴, 等. GA反義基因對裸鼠胃癌移植瘤細胞凋亡的影響 [J]. 中國普外基礎與臨床雜志, 2008; 15(1): 4-7.
16. 黃喆, 郭克建, 何三光. 柳氮磺胺吡啶和5-氟尿嘧啶對裸鼠皮下移植瘤胰腺癌細胞BxPC-3凋亡基因的影響 [J]. 中國普外基礎與臨床雜志, 2008; 15(8): 550-555.
17. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial [J]. Lancet, 2001; 358(9286): 966-970.
18. Metzinger DS, Taylor DD, Gercel-Taylor C. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines [J]. Cancer Lett, 2006; 236(2): 302-308.
19. 萬繼英, 韓庶勇. 腫瘤實驗動物模型的建立及應用研究進展 [J]. 醫學綜述， 2009; 15(19): 2959-2961.
20. Yoshiba S, Ito D, Nagumo T, et al. Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest [J]. Oral Oncol, 2009; 45(2): 109-115.
21. 梁永鉅，符立梧，馮海林, 等. KBv200裸鼠移植瘤模型的建立及其耐藥特性的探討 [J] . 中國藥理學通報, 2000; 16(6)： 705-707.
22. Henss H, Fiebig HH, Meinhardt K, et al. Clonal growth of human tumor xenografts. First experiences in drug testing [J]. J Cancer Res Clin Oncol, 1984; 108(2): 233-235.
23. Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development [J]. Eur J Cancer, 2004; 40(6): 827-836.
24. Prenen H, Deroose C, Vermaelen P, et al. Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography [J]. Anticancer Res, 2006; 26(2A): 1247-1252.
25. Zhang YH, Wu Q, Xiao XY, et al. Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell [J]. Cancer Lett, 2010; 291(1): 76-82.
26. Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic plafform [J]. Lancet Oncol, 2002; 3(1): 17-26.

《中國普外基礎與臨床雜志》

人胃癌SGC-7901/HCPT裸鼠移植瘤的建立及生物學特性研究

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

人胃癌SGC-7901/HCPT裸鼠移植瘤的建立及生物學特性研究

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料